Targeting HTLV-I latency in Adult T-cell Leukemia/Lymphoma by Ramos, Juan C et al.
MEETING ABSTRACT Open Access
Targeting HTLV-I latency in Adult T-cell
Leukemia/Lymphoma
Juan C Ramos
*, Ngoc Toomey, Luis Diaz, Phillip Ruiz, Glen Barber, William Harrington Jr
From 15th International Conference on Human Retroviruses: HTLV and Related Viruses
Leuven and Gembloux, Belgium. 5-8 June 2011
Adult T-cell leukemia/lymphoma (ATLL) is highly che-
motherapy resistant. The combination of AZT and
interferon (IFN) is a first line treatment option for the
leukemic forms of ATLL. We and others have demon-
strated AZT/IFN can effectively suppress ATLL long-
term; however, these drugs fail to eradicate malignant
ATLL clones. At our institution we have recently estab-
lished a clinical trial for ATLL using AZT/IFN in com-
bination with the inexpensive histone deacelytase
(HDAC) inhibitor valproic acid (VPA) during the main-
tenance treatment phase. Histone acetylation can result
in HTLV-I promoter activation and viral transcription.
We hypothesized that HDAC inhibitors would re-acti-
vate latent HTLV-I in ATLL cells harboring intact pro-
virus and help eliminate residual disease after
cytoreductive treatment. We have exciting preliminary
data which suggest we can achieve this. So far, we have
enrolled 13 subjects with acute-type ATLL in our study.
We observed a serial decrease in clonal ATLL disease
followed by molecular clearance by multiplex PCR in
one subject after VPA treatment. We had not seen such
effect previously in long-term responders treated with
AZT/IFN alone. Using fresh ATLL cells from this sub-
ject we augmented HTLV-I expression and induced cell
death ex vivo after treatment with the newer HDAC
inhibitor vorinostat. We are currently testing other
newly available HDAC inhibitors in our pre-clinical
models. The dual anti-neoplastic and viral inducing
roles of HDAC inhibitors can be exploited in the treat-
ment of ATLL. This exciting approach may help
advance the cure for this disease. We will present our
interim clinical trial results at the conference.
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